Telix Pharmaceuticals (TLX) Non-Current Deffered Revenue (2023 - 2024)
Telix Pharmaceuticals (TLX) reported Non-Current Deffered Revenue of $2.2 million for Q4 2024, down 72.84% year-over-year from $7.9 million in Q1 2024, and down 72.84% quarter-over-quarter from $7.9 million in Q4 2023.
Telix Pharmaceuticals (TLX) Non-Current Deffered Revenue (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLX) has 2 years of Non-Current Deffered Revenue data on file, last reported at $2.2 million in Q4 2024.
- Non-Current Deffered Revenue for Q4 2024 came in at $2.2 million, down 72.84% year-over-year; the trailing twelve-month figure through Dec 2024 was $2.2 million (down 72.84% YoY), and the FY2024 annual result was $2.0 million, down 75.53% from the prior year.
- Non-Current Deffered Revenue retreated to $2.2 million in Q4 2024 per TLX's latest filing, from $7.9 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $7.9 million in Q4 2023 and troughed at $2.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Telix Pharmaceuticals | 4.81 Bn | 4.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 7.92 Mn |